NO20045679D0 - Nye fysiologisk aktive substanser - Google Patents

Nye fysiologisk aktive substanser

Info

Publication number
NO20045679D0
NO20045679D0 NO20045679A NO20045679A NO20045679D0 NO 20045679 D0 NO20045679 D0 NO 20045679D0 NO 20045679 A NO20045679 A NO 20045679A NO 20045679 A NO20045679 A NO 20045679A NO 20045679 D0 NO20045679 D0 NO 20045679D0
Authority
NO
Norway
Prior art keywords
active substances
physiologically active
new physiologically
new
substances
Prior art date
Application number
NO20045679A
Other languages
English (en)
Other versions
NO20045679L (no
Inventor
Jun Niijima
Mitsuo Nagai
Yoshihiko Kotake
Yoshio Fukuda
Regina Mikie Kanada
Takashi Nakashima
Masashi Yoshida
Toshio Tsuchida
Original Assignee
Mercian Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mercian Corp filed Critical Mercian Corp
Publication of NO20045679D0 publication Critical patent/NO20045679D0/no
Publication of NO20045679L publication Critical patent/NO20045679L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20045679A 2002-05-29 2004-12-28 Nye fysiologik aktive substanser NO20045679L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002155853 2002-05-29
JP2002223355 2002-07-31
JP2003063176 2003-03-10
PCT/JP2003/006779 WO2003099813A1 (fr) 2002-05-29 2003-05-29 Nouvelles substances physiologiquement actives

Publications (2)

Publication Number Publication Date
NO20045679D0 true NO20045679D0 (no) 2004-12-28
NO20045679L NO20045679L (no) 2005-02-28

Family

ID=29587471

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045679A NO20045679L (no) 2002-05-29 2004-12-28 Nye fysiologik aktive substanser

Country Status (17)

Country Link
US (4) US20060009439A1 (no)
EP (3) EP1508570A4 (no)
JP (2) JP4491341B2 (no)
KR (1) KR100954401B1 (no)
CN (2) CN1665807A (no)
AU (1) AU2003241927C1 (no)
BR (1) BR0311331A (no)
CA (1) CA2486728C (no)
ES (1) ES2603803T3 (no)
IL (2) IL165388A0 (no)
IS (1) IS7571A (no)
MX (1) MXPA04011885A (no)
NO (1) NO20045679L (no)
NZ (1) NZ536778A (no)
PL (1) PL373806A1 (no)
TW (1) TWI334866B (no)
WO (1) WO2003099813A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI311558B (en) 2001-02-01 2009-07-01 Mercian Corporatio Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
AU2003252299A1 (en) 2002-07-31 2004-02-16 Eisai Co., Ltd. Novel physiologically active substance
NZ540103A (en) * 2002-11-29 2007-05-31 Mercian Corp Process for producing macrolide compound
CA2546614A1 (en) 2003-11-27 2005-06-09 Mercian Corporation Dna participating in hydroxylation of macrolide compound
EP1710244A4 (en) * 2004-01-29 2009-06-17 Eisai R&D Man Co Ltd METHOD FOR STABILIZING A MACROLIDE COVERAGE
ATE469985T1 (de) * 2004-02-06 2010-06-15 Eisai R&D Man Co Ltd Verfahren zur untersuchung der empfindlichkeit einer krebszelle gegenüber einem antikrebsmittel
AU2005265443B2 (en) 2004-07-20 2008-09-04 Eisai R & D Management Co., Ltd DNA coding for polypeptide participating in biosynthesis of pladienolide
CN101282967B (zh) * 2005-10-13 2011-01-26 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
WO2008016187A1 (fr) 2006-08-02 2008-02-07 Eisai R & D Management Co., Ltd. Molécule cible de pladiénolide, composé capable de se lier à la molécule cible et procédé de criblage pour rechercher le composé
US20090325978A1 (en) * 2006-08-14 2009-12-31 Katsumi Onai Stable lyophilized preparation
US7790887B2 (en) * 2007-01-29 2010-09-07 Eisai R&D Management Co., Ltd. Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same
JPWO2008111464A1 (ja) 2007-03-05 2010-06-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライシング異常を指標とする抗ガン剤の作用検定方法
JPWO2008111466A1 (ja) 2007-03-05 2010-06-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 遺伝子の発現量減少を指標とする抗ガン剤の作用検定方法
US20080312317A1 (en) * 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
CA2692644A1 (en) 2007-07-06 2009-01-15 Toshio Tsuchida Method for producing macrolide compound and production intermediate therof
GB0821539D0 (en) * 2008-11-25 2008-12-31 Merlion Pharmaceuticals Pte Ltd Therapeutic compounds and their use
SI3143016T1 (sl) 2014-05-15 2019-04-30 Eisai R&D Management Co., Ltd. Spojine pladienolid piridina in postopki uporabe
US10889866B2 (en) 2015-09-01 2021-01-12 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic SF3B1 mutants
RU2021102393A (ru) 2015-11-18 2021-03-17 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Твердые формы пладиенолидпиридиновых соединений и способы их применения
WO2018170129A1 (en) 2017-03-15 2018-09-20 Eisai Co., Ltd Spliceosome mutations and uses thereof
BR112020020792A2 (pt) 2018-04-09 2021-01-12 Eisai R&D Management Co., Ltd. Certos compostos de pladienolida e métodos de uso
SG11202009907XA (en) 2018-04-12 2020-11-27 Eisai R&D Man Co Ltd Pladienolide derivatives as spliceosome targeting agents for treating cancer
EP3801523A2 (en) 2018-06-01 2021-04-14 Eisai R&D Management Co., Ltd. Methods of using splicing modulators
TW202015739A (zh) 2018-06-01 2020-05-01 日商衛材R&D企管股份有限公司 剪接調節抗體-藥物結合物及其使用方法
RU195959U1 (ru) * 2019-09-23 2020-02-11 Анна Александровна Золотенкова Устройство для механической нейростимуляции языка
AU2021284401A1 (en) 2020-06-05 2023-01-05 Eisai R&D Management Co., Ltd. Anti-BCMA antibody-drug conjugates and methods of use
TW202233187A (zh) 2020-11-04 2022-09-01 日商衛材R&D企管股份有限公司 骨髓發育不良症候群（ｍｄｓ）之生物標記物及其使用方法
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL27183A (en) 1966-02-01 1970-07-19 Upjohn Co Parenteral composition comprising freeze dried mannitol
JPS6054933B2 (ja) 1978-01-27 1985-12-03 小野薬品工業株式会社 プロスタグランジン及びプロスタグランジン類似化合物製剤の安定化法
JPH04352783A (ja) 1991-05-27 1992-12-07 Taisho Pharmaceut Co Ltd １２員環マクロライド系化合物
CA2188682A1 (en) * 1994-04-25 1995-11-02 Tokuyuki Kuroda Method for stabilizing compound dx-52-1 and lyophilized composition thereof
EP1192147A1 (en) * 1999-06-03 2002-04-03 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Mycolactone and related compounds, compositions and methods of use
US6391903B1 (en) 1999-09-09 2002-05-21 Sankyo Company, Limited Triazole derivatives having antifungal activity
JP3240129B1 (ja) 1999-09-09 2001-12-17 三共株式会社 トリアゾール抗真菌剤
JP4953501B2 (ja) 1999-09-30 2012-06-13 大塚化学株式会社 ３−セフェム誘導体結晶の製造方法
US6562602B2 (en) 2000-08-03 2003-05-13 Kosan Biosciences, Inc. Fermentation and purification of mycolactones
TWI311558B (en) * 2001-02-01 2009-07-01 Mercian Corporatio Novel physiologically active substance
TWI233361B (en) * 2001-04-13 2005-06-01 Gen Hospital Corp Methods of preventing UVB-induced skin damage
TWI334866B (en) * 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
JP2004269488A (ja) * 2002-06-06 2004-09-30 Hayashibara Biochem Lab Inc 結晶α−Ｄ−グルコシルα−Ｄ−ガラクトシドとこれを含有する糖質及びこれらの製造方法並びに用途
CN1671856B (zh) * 2002-07-31 2010-05-12 卫材R&D管理株式会社 生理活性物质
AU2003252299A1 (en) * 2002-07-31 2004-02-16 Eisai Co., Ltd. Novel physiologically active substance
NZ540103A (en) * 2002-11-29 2007-05-31 Mercian Corp Process for producing macrolide compound
US20050106275A1 (en) 2003-05-02 2005-05-19 Chen Su Morinda citrifolia-based formulation for inhibiting metastasis of carcinogenic cells
KR100732100B1 (ko) * 2003-05-07 2007-06-27 에자이 알앤드디 매니지먼트 가부시키가이샤 메틸코발라민 함유 동결 건조 제제 및 그의 제조 방법
EP1710244A4 (en) 2004-01-29 2009-06-17 Eisai R&D Man Co Ltd METHOD FOR STABILIZING A MACROLIDE COVERAGE
JP2007269628A (ja) 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
JPWO2006075690A1 (ja) 2005-01-14 2008-06-12 小野薬品工業株式会社 安定な医薬組成物
WO2006121104A1 (ja) 2005-05-11 2006-11-16 Eisai R & D Management Co., Ltd. ピペリジン環を有するインドール誘導体の結晶およびその製法
CN101282967B (zh) * 2005-10-13 2011-01-26 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
US20090325978A1 (en) * 2006-08-14 2009-12-31 Katsumi Onai Stable lyophilized preparation
US7790887B2 (en) * 2007-01-29 2010-09-07 Eisai R&D Management Co., Ltd. Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
IL165388A0 (en) 2006-01-15
TW200406408A (en) 2004-05-01
AU2003241927B2 (en) 2009-06-18
PL373806A1 (en) 2005-09-19
NO20045679L (no) 2005-02-28
US20080255146A1 (en) 2008-10-16
US7893068B2 (en) 2011-02-22
MXPA04011885A (es) 2005-09-12
CN1665807A (zh) 2005-09-07
KR100954401B1 (ko) 2010-04-26
US20060009439A1 (en) 2006-01-12
EP2266978A1 (en) 2010-12-29
AU2003241927C1 (en) 2009-11-05
EP2266978B1 (en) 2015-05-20
TWI334866B (en) 2010-12-21
CA2486728C (en) 2011-07-05
KR20050033552A (ko) 2005-04-12
AU2003241927B8 (en) 2009-07-23
EP1508570A1 (en) 2005-02-23
US7550503B2 (en) 2009-06-23
CN1665807B (zh) 2013-09-11
JP4491341B2 (ja) 2010-06-30
CA2486728A1 (en) 2003-12-04
IS7571A (is) 2004-11-29
US20060241171A1 (en) 2006-10-26
NZ536778A (en) 2007-03-30
ES2603803T3 (es) 2017-03-01
EP1508570A4 (en) 2007-08-15
US7619100B2 (en) 2009-11-17
IL165388A (en) 2013-03-24
EP2927228A1 (en) 2015-10-07
BR0311331A (pt) 2005-05-10
US20080275059A1 (en) 2008-11-06
WO2003099813A1 (fr) 2003-12-04
EP2927228B1 (en) 2016-09-07
JPWO2003099813A1 (ja) 2005-09-22
AU2003241927A1 (en) 2003-12-12
JP2010132693A (ja) 2010-06-17

Similar Documents

Publication Publication Date Title
NO20045679D0 (no) Nye fysiologisk aktive substanser
PT1501534E (pt) Formulacoes farmaceuticas
DE60324099D1 (de) Arzneistoffhaltiger tampon
NO20044588L (no) Nye forbindelser
NO20044432L (no) Nye forbindelser
IS7894A (is) Skammtaform með ofnæmisvaka
DE60332094D1 (de) Aktive pulsspektrophotometrie
DK1523493T3 (da) Nye tubulysinanaloge
ATE383771T1 (de) Fungizide wirkstoffkombinationen
IS7946A (is) Lyf
DE60312097D1 (de) Rundballenpresse
EP1548121A4 (en) NEW PHYSIOLOGICALLY ACTIVE SUBSTANCES
DE60311517D1 (de) Multiionophore membranelektrode
DE50311719D1 (de) Rundballenpresse
DE60219211D1 (de) Sterilisator
DE50303220D1 (de) Sämaschine
NO20043576L (no) Pharmaceutical formulation comprising melatonin
DE50304722D1 (de) Fungizide Wirkstoffkombinationen
DE60324491D1 (de) Kultivator
NO20026285D0 (no) Nye peptider
ITMI20020161A0 (it) Filtro attivo
NO20044098L (no) Nye forbindelser
DE10393889D2 (de) Medikament-Dosimeter-Kombipackung
DE50309824D1 (de) Bodenbearbeitungsgerät
NO20050026L (no) Nye benzodioksoler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application